CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg): A Triple‑Pathway Tool for Advanced Growth Hormone Research

If your research delves into the complex neuroendocrine regulation of the growth hormone (GH) axis, the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) offers a uniquely comprehensive experimental platform.

This 9 mg formulation combines three well‑characterised GH secretagogues—CJC-1295 (Mod GRF 1-29), a modified GHRH analogue; Ipamorelin, a selective ghrelin receptor agonist; and GHRP-2, a potent growth hormone‑releasing peptide—each acting through distinct yet complementary mechanisms at the pituitary and hypothalamic levels. By simultaneously targeting the GHRH receptor and the growth hormone secretagogue receptor (GHS‑R1a) with two distinct agonists, this blend allows researchers to model the synergistic interplay that governs GH pulsatility, providing deeper insight into the circuits that regulate endocrine signalling, metabolic homeostasis, and tissue repair.

At Chinese Grey Peptides, we supply high‑purity CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to ≥99% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into GH regulation, IGF‑1 signalling, and metabolic research begin with uncompromising quality.

What Is the CJC-1295 & Ipamorelin & GHRP‑2 Blend and How Does It Work?

To fully appreciate the research potential of the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg), it is essential to understand the distinct yet convergent mechanisms of its three components.

CJC-1295 (Mod GRF 1-29): The Stabilised GHRH Analogue

CJC-1295 (Mod GRF 1-29), also referred to as CJC-1295 without DAC, is a modified analogue of growth hormone‑releasing hormone (GHRH). It is a 29‑amino‑acid peptide with four amino acid substitutions (D‑Ala², Gln⁸, Ala¹⁵, Leu²⁷) that enhance its activity and render it resistant to proteolytic degradation. Unlike CJC‑1295‑DAC, which contains a drug affinity complex and has a half‑life of approximately 6‑8 days, Mod GRF 1‑29 does not contain the DAC moiety and has a shorter half‑life of approximately 30 minutes.

As a GHRH analogue, CJC‑1295 acts on GHRH receptors in the anterior pituitary gland to stimulate the release of human growth hormone in a pulsatile manner. The version without DAC creates short, sharp GH pulses that closely mimic natural physiology.

Ipamorelin: The Selective Ghrelin Receptor Agonist

Ipamorelin is a synthetic pentapeptide (Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂) that was first described as “the first selective growth hormone secretagogue”. Its defining pharmacological advantage is GH stimulation without elevating cortisol, ACTH, or prolactin, even at doses well above those required for GH stimulation.

Ipamorelin binds to the growth hormone secretagogue receptor (GHS‑R1a), inducing intracellular signalling cascades involving calcium mobilisation and protein kinase C. Its high selectivity for GH release makes it a cleaner tool for studying GH dynamics.

GHRP-2: The Potent Growth Hormone‑Releasing Peptide

GHRP-2 (Pralmorelin, KP‑102) is a synthetic hexapeptide classified as part of the growth hormone secretagogue family. It has been widely explored for its strong binding affinity to the ghrelin receptor and its robust GH‑releasing activity. Like ipamorelin, it acts through the same receptor, stimulating GH release via phospholipase C and intracellular calcium flux.

Beyond somatotroph GH release, GHRP-2 activates hypothalamic circuits that suppress somatostatin release and stimulate endogenous GHRH secretion, creating a feed‑forward loop. GHRP-2 also mildly stimulates ACTH, cortisol, and prolactin release.

Mechanism of Synergy: Triple‑Pathway Activation

The scientific rationale for combining CJC‑1295 (Mod GRF 1‑29), Ipamorelin, and GHRP‑2 lies in their convergent yet distinct mechanisms. When conceptualised as a blended research framework, these peptides invite investigation into how complementary properties might interact to yield distinct hormonal output patterns:

• CJC‑1295 (Mod GRF 1‑29) provides the primary “message” to initiate GH production by activating the classical GHRH receptor pathway through Gs‑coupled adenylyl cyclase signalling, creating a sustained signalling foundation.

• Ipamorelin enhances the amplitude of that response by engaging the ghrelin/secretagogue receptor system through Gq‑coupled phospholipase C signalling, inducing a pulsatile release pattern of GH that may mimic endogenous rhythmicity.

• GHRP-2 further reinforces the ghrelin receptor axis through its strong binding affinity and robust, transient GH‑releasing activity, while also suppressing somatostatin and stimulating endogenous GHRH release.

GHRH + GHRP combinations produce GH release greater than the sum of either agent alone, with studies demonstrating that combining GHRP-2 with GHRH analogs produces synergistic GH release. This triple‑pathway activation enables researchers to model the complex, multi‑stage process of GH regulation—from receptor‑level signalling to systemic metabolic outcomes.

Key Research Applications for the CJC-1295 & Ipamorelin & GHRP‑2 Blend (9mg)

The CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) is a versatile tool with applications spanning several domains of endocrinological and metabolic research.

1. Growth Hormone Axis & Pituitary Function Studies

This blend provides a powerful model for investigating the hypothalamic‑pituitary‑somatotropic axis. Researchers can use it to study:

• The synergistic effects of GHRH and ghrelin pathway co‑activation on GH synthesis, storage, and pulsatile release

• The distinct contributions of GHRH‑mediated and ghrelin‑mediated signalling to overall GH secretion

• The dynamics of GH pulse amplitude and frequency in response to triple‑pathway stimulation

• The potential for sustained baseline receptor activity layered with pulsatile peaks to yield unique hormonal output patterns

2. Metabolic & Body Composition Research

By stimulating endogenous GH release through three pathways, this blend provides a model for studying the downstream metabolic effects of GH and IGF‑1 elevation. Research applications include:

• Lipid Metabolism: Exploring the role of GH in lipolysis and fat metabolism

• Glucose Homeostasis: Investigating how GH modulation impacts glucose regulation and insulin sensitivity

• Body Composition: Studying how enhanced GH secretion may influence lean tissue accrual and reduce adipose deposition

• Adipose Tissue Distribution: Examining how both peptides might impact the distribution of adipose tissue through their impacts on growth hormone secretion

3. Receptor Pharmacology & Signalling Research

The blend may offer a multifaceted research modality for probing endogenous growth hormone axis mechanics. Researchers can use it to:

• Investigate the complex interplay between the GHRH and ghrelin systems

• Study the downstream signalling pathways activated by GHRH and ghrelin receptor co‑stimulation

• Characterise dual‑GPCR signalling and second‑messenger outputs in the context of GH regulation

• Explore receptor bias and systems‑level integration within the organism

4. Appetite & Metabolic Regulation Research

GHRP-2’s activation of hypothalamic NPY/AgRP neurons involved in appetite regulation provides a distinct research angle. Research applications include:

• Appetite Regulation Studies: Investigating GHRP-2’s central mechanisms in feeding behaviour and energy balance

• Hypothalamic Circuitry: Studying the interaction between ghrelin receptor agonists and hypothalamic neuropeptide Y pathways

• Metabolic Adaptation: Exploring how appetite‑stimulating signals interact with GH‑mediated metabolic effects

5. Pulsatile GH & Neuroendocrine Research

The short half‑life of CJC‑1295 without DAC (approximately 30 minutes) makes it ideal for studying pulsatile GH release. Research applications include:

• Pulsatile GH Dynamics: Investigating the physiological significance of pulsatile GH secretion patterns

• Neuroendocrine Rhythms: Studying how pulsatile GHRH stimulation affects the natural circadian rhythm of GH secretion

• Somatotroph Sensitivity: Exploring how pulsatile stimulation preserves somatotroph sensitivity and avoids desensitisation

Chemical & Physical Specifications for CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Accurate characterisation of the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) is essential for reproducible experimental design.

Note: The 9 mg mass represents the total peptide weight of the blend. The exact ratio of CJC‑1295 (Mod GRF 1‑29) to Ipamorelin to GHRP‑2 is determined by the formulation (contact for details). The blend is supplied in a single lyophilised vial. This product is intended strictly for in‑vitro and laboratory research use only (RUO). Not for human or animal use.

Reconstitution & Handling Protocol for the CJC-1295 & Ipamorelin & GHRP‑2 Blend (9mg)

Proper reconstitution of the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) is critical for maintaining the structural integrity and biological activity of all three peptides.

Step 1 – Preparation

• Bring the sealed blend vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the blend vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 9 mg per 0.9 mL of diluent, yielding a 10 mg/mL total peptide concentration.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted peptide blend into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles.

• Once thawed, store at 2‑8°C and use within 14 days.

Concentration Reference Table for CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Adjust diluent volume based on your experimental requirements. The exact concentration of each individual peptide within the blend is determined by the formulation’s component ratio.

Storage & Stability Guidelines for CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Why Choose Chinese Grey Peptides for the CJC-1295 & Ipamorelin & GHRP‑2 Blend?

As an authentic licensed peptide supplier based in the USA, we supply the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed ≥99% for each component, every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• USA‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO). This peptide blend is intended strictly for laboratory research, analytical, or reference use, where permitted by local regulations. Not for human or veterinary use.

Researchers across the United States—including those at leading institutions—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

What is the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)?
It is a research‑grade formulation combining CJC‑1295 (Mod GRF 1‑29, a modified GHRH analogue), Ipamorelin (a selective ghrelin receptor agonist), and GHRP‑2 (a potent growth hormone‑releasing peptide). It is used as a triple‑pathway tool to study growth hormone stimulation, IGF‑1 signalling, and metabolic research.

How does each component work?
CJC‑1295 (Mod GRF 1‑29) binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release via cAMP/PKA signalling. Ipamorelin binds to the growth hormone secretagogue receptor (GHS‑R1a), amplifying GH release without elevating cortisol, ACTH, or prolactin. GHRP‑2 acts through the same receptor, stimulating GH release via phospholipase C and intracellular calcium flux, while also suppressing somatostatin and stimulating endogenous GHRH release.

What is the proposed synergy between CJC‑1295, Ipamorelin, and GHRP‑2?
CJC‑1295 provides the primary stimulus to initiate GH production, while Ipamorelin and GHRP‑2 enhance the amplitude of that response through the ghrelin receptor axis. GHRP‑2 also suppresses somatostatin, creating a permissive environment for maximal GH pulse amplitude. GHRH + GHRP combinations produce GH release greater than the sum of either agent alone.

What distinguishes Ipamorelin from GHRP‑2 in research?
Ipamorelin is highly selective for GH release, producing negligible effects on cortisol, ACTH, or prolactin. GHRP‑2 generates robust GH output alongside measurable increases in ACTH, cortisol, prolactin, and appetite‑stimulating signals. Both are used to study different aspects of GH regulation.

 What purity does your CJC‑1295 & Ipamorelin & GHRP‑2 Blend (9mg) meet?
Each component is tested to ≥99% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

 How should I reconstitute this peptide blend?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake.

 How should I store reconstituted peptide blends?
Reconstituted blends should be stored at 2‑8°C and used within 14 days. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

What is the difference between CJC‑1295 with DAC and without DAC?
CJC‑1295 without DAC (Mod GRF 1‑29) has a half‑life of approximately 30 minutes and supports a pulsatile release pattern that closely mimics natural physiology. CJC‑1295 with DAC has a half‑life of approximately 6‑8 days and produces sustained, continuous GH elevation.

 Is this peptide blend legal to purchase in the USA for research?
Yes. This blend is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United States for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: CJC‑1295, Ipamorelin, and GHRP‑2 are not FDA‑approved for therapeutic use and are prohibited by the World Anti‑Doping Agency (WADA) for athletic use.

 Does Chinese Grey Peptides ship internationally?
Yes. We ship across the UK, Europe (France, Germany, Spain, Sweden, Italy), and the USA from our US warehouse. Wholesale pricing is available for bulk orders.

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

1. Shop Page
2. Bulk Orders Page
3. Contact Page
4. Shipping & Return Page
5. Peptide Purity Page

• PubChem CJC-1295
• PubChem Ipamorelin
• PubChem Pralmorelin / GHRP-2
• FDA compounding-risk page for CJC-1295
• WADA Growth Hormone Releasing Factors Testing Guide
• FDA Gram Peptides warning letter
• Google Product Structured Data

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Ships to USA, Canada, UK & Europe

Chinese Grey Peptides supports shipping to the USA, Canada, the United Kingdom, France, Germany, Spain, Sweden, Italy, and Europe where permitted.

Shipping support may include:

• Order processing updates
• Packaging support
• Tracking information where available
• Wholesale shipment planning
• Destination-based shipping review
• Customer support during transit

Shipping times may vary by order size, carrier, destination, customs process, product status, and local requirements.

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Why Choose Chinese Grey Peptides?

Chinese Grey Peptides focuses on quality, support, and clear communication. We help buyers review product details before placing an order.

Customers choose us for:

• Professional peptide supplier support
• Small and wholesale order options
• Product documentation support
• HPLC testing information where available
• Mass Spectrum documentation where available
• International shipping support
• Responsive communication
• Clear order assistance before payment

We aim to make the buying process transparent, professional, and documentation-focused.

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Important Compliance Notice

CJC-1295 Ipamorelin GHRP-2 Blend 9mg may be regulated differently depending on the country, product type, labeling, intended use, buyer type, and destination. Chinese Grey Peptides does not provide medical advice, dosing instructions, injection guidance, growth hormone claims, anti-aging claims, fat-loss claims, muscle-growth claims, recovery claims, athletic-performance claims, bodybuilding claims, disease claims, treatment claims, or personal-use recommendations.

Customers are responsible for understanding and following all local laws, import rules, prescription requirements, compounding rules, sport-governing rules, labeling rules, and permitted-use requirements before ordering.

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

From its innovative design as a triple‑pathway GH secretagogue blend to its well‑documented role in modelling the synergistic interplay between the GHRH and ghrelin systems, the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) provides a uniquely versatile platform for advanced endocrinological and metabolic research.

Its ability to stimulate endogenous GH release through three distinct yet convergent pathways—CJC‑1295 providing sustained GHRH‑receptor engagement, Ipamorelin amplifying through selective ghrelin receptor activation, and GHRP‑2 reinforcing the ghrelin receptor axis while suppressing somatostatin—supported by research demonstrating synergistic GH release greater than the sum of either agent alone, makes it a valuable addition to any laboratory investigating the GH/IGF‑1 axis. By choosing high‑purity, lab‑verified CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) from Chinese Grey Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade research peptides delivered directly to your facility in the USA, UK, or Europe.CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg),CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg),CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg),CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg),CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg),CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)